Lisinopril vs Amlodipine: Cost, Access, and Head-to-Head Comparison

How Much Do Lisinopril and Amlodipine Cost Without Insurance?

Both medications rank among the least expensive prescription drugs in the United States, and their cash prices are nearly identical at retail pharmacies. Generic lisinopril 10 mg (30 tablets) typically costs $3 to $10 at chains like Walmart, Costco, and CVS. Generic amlodipine 5 mg (30 tablets) falls into the same range, with most pharmacies listing it between $3 and $12.

The pricing parity between these two drugs is not coincidental. Both lost patent protection decades ago. Lisinopril (originally marketed as Prinivil and Zestril) went generic in 2002. Amlodipine (originally Norvasc) followed in 2007. The result is a saturated generic market with dozens of manufacturers competing on both molecules. According to the FDA's Orange Book, there are over 20 approved ANDA holders for each compound.

Discount pharmacy programs further compress the already low prices. Walmart's $4 prescriptions program, Costco Member Prescription Program, and Mark Cuban's Cost Plus Drugs all carry both lisinopril and amlodipine at or below $5 for a 30-day supply. GoodRx coupons routinely bring the price under $4 at participating pharmacies. For patients on fixed incomes or without prescription coverage, the practical cost difference between these two medications is negligible. It often comes down to which pharmacy is closest.

One scenario where cost diverges: brand-name formulations. Norvasc brand tablets can still list above $100 per month at some pharmacies, while Prinivil brand pricing is similar. There is no clinical reason to prescribe brand over generic for either drug, and the FDA considers all approved generics therapeutically equivalent to their reference products.

Insurance Formulary Placement and Prior Authorization

Both lisinopril and amlodipine sit on Tier 1 of virtually every commercial health plan and Medicare Part D formulary in the country, meaning they carry the lowest possible copay. Neither drug requires prior authorization or step therapy under standard formulary rules.

A 2017 analysis published in the Journal of the American Heart Association examined formulary coverage of antihypertensive medications across Medicare Part D plans and found that ACE inhibitors and dihydropyridine calcium channel blockers had near-universal Tier 1 placement, with coverage rates exceeding 98% for both classes. This pattern holds across Medicaid programs as well. Every state Medicaid preferred drug list reviewed by the HealthRX editorial team includes both lisinopril and amlodipine without restriction.

For patients enrolled in high-deductible health plans (HDHPs) with health savings accounts, the distinction between formulary tiers matters less because they pay cash prices until their deductible is met. In this context, both drugs are so inexpensive that the out-of-pocket burden is minimal regardless of plan design. A patient filling lisinopril 20 mg or amlodipine 5 mg monthly will spend roughly $36 to $60 per year at cash prices.

Combination formulations tell a slightly different story. Amlodipine-benazepril (Lotrel generic) and amlodipine-valsartan (Exforge generic) are also generic but priced higher, typically $15 to $40 per month. Lisinopril-hydrochlorothiazide (Zestoretic generic) remains under $10 per month. Patients who need dual therapy may find that the specific combination product affects their total cost, even though the individual components are cheap.

ALLHAT: The Largest Head-to-Head Antihypertensive Trial

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) remains the most relevant source of direct comparative data between lisinopril and amlodipine. Published in JAMA in 2002, ALLHAT randomized 33,357 patients aged 55 and older with hypertension and at least one additional coronary heart disease risk factor to one of four arms: chlorthalidone (a thiazide diuretic), amlodipine, lisinopril, or doxazosin (discontinued early).

The primary outcome was combined fatal coronary heart disease and nonfatal myocardial infarction. Results showed no significant difference between the amlodipine arm and the chlorthalidone arm (RR 0.98 to 95% CI 0.90 to 1.07) or between the lisinopril arm and chlorthalidone (RR 0.99 to 95% CI 0.91 to 1.08). The two drugs performed comparably on this endpoint.

Secondary outcomes told a more complex story. The lisinopril arm had a 15% higher relative risk of stroke compared to chlorthalidone (RR 1.15 to 95% CI 1.02 to 1.30). The amlodipine arm showed a 35% higher relative risk of heart failure compared to chlorthalidone (RR 1.38 to 95% CI 1.25 to 1.52). These differences were driven partly by blood pressure control. Lisinopril achieved slightly less blood pressure reduction than chlorthalidone in Black participants, a finding the ALLHAT investigators attributed to the reduced efficacy of ACE inhibitor monotherapy in this population.

Dr. Barry Davis, ALLHAT's lead biostatistician at the University of Texas School of Public Health, stated in the original publication: "Thiazide-type diuretics are superior in preventing one or more major forms of CVD and are less expensive. They should be preferred for first-step antihypertensive therapy."

The trial did not compare lisinopril directly to amlodipine as a primary contrast. Both were compared against chlorthalidone. Any comparison between the two drugs must be interpreted through this three-way design, which limits the strength of direct lisinopril-versus-amlodipine conclusions.

ASCOT-BPLA: Amlodipine's Strongest Trial Evidence

The Anglo-Scandinavian Cardiac Outcomes Trial, Blood Pressure Lowering Arm (ASCOT-BPLA) was a randomized trial of 19,257 patients with hypertension and at least three additional cardiovascular risk factors. It compared an amlodipine-based regimen (with perindopril added as needed) to an atenolol-based regimen (with bendroflumethiazide added as needed).

The trial was stopped early at a median follow-up of 5.5 years because of significant differences favoring the amlodipine-based arm. The amlodipine group experienced 16% fewer cardiovascular events (HR 0.84, P=0.0003) and 23% fewer strokes (HR 0.77, P=0.0003) compared to the atenolol group. All-cause mortality was 11% lower (HR 0.89, P=0.025).

This trial did not include a lisinopril arm. It compared amlodipine (a CCB) to atenolol (a beta-blocker), so it does not provide direct evidence of amlodipine's superiority over ACE inhibitors. It does, however, position amlodipine-based regimens as a preferred choice over older beta-blocker strategies for primary prevention in hypertensive patients with multiple risk factors.

Professor Peter Sever, the principal investigator from Imperial College London, noted in the Lancet publication: "These data support the use of calcium channel blocker-based regimens as first-line therapy in patients similar to those studied in ASCOT."

When ALLHAT and ASCOT-BPLA are viewed together, a practical picture emerges: amlodipine has strong standalone trial evidence from ASCOT, while lisinopril's ALLHAT performance was solid but showed specific weaknesses in stroke prevention and in Black patient subgroups compared to thiazide diuretics. Neither trial establishes one drug as clearly superior to the other for the general hypertensive population.

Side Effects That Influence Switching Decisions

The most common reason patients switch between lisinopril and amlodipine is side effects, not cost. Each drug has a distinctive and well-characterized adverse effect profile that makes it intolerable for a subset of users.

Lisinopril causes a persistent dry cough in 5% to 20% of patients, a class effect of all ACE inhibitors linked to bradykinin accumulation in the lungs. A meta-analysis in the Annals of Internal Medicine estimated the incidence at approximately 10% across populations, with higher rates in women and patients of East Asian descent. The cough is not dangerous but can be severe enough to disrupt sleep and daily activities. It resolves within 1 to 4 weeks of discontinuation.

Angioedema is a rare but serious risk with ACE inhibitors, occurring in approximately 0.1% to 0.7% of patients, with Black patients experiencing a 2- to 4-fold higher incidence. Angioedema requires immediate discontinuation and is an absolute contraindication to rechallenge with any ACE inhibitor.

Amlodipine's signature side effect is dose-dependent peripheral edema, particularly in the ankles and lower legs. At the 5 mg dose, edema occurs in roughly 3% of patients. At 10 mg, the rate climbs to approximately 10.8%, according to the prescribing label filed with the FDA. The edema is caused by arteriolar vasodilation, not fluid retention, which means diuretics do not reliably resolve it. Adding an ACE inhibitor or ARB can reduce the edema through venodilation on the post-capillary side, which is one rationale for combination therapy.

Other notable differences: lisinopril carries a risk of hyperkalemia (particularly in patients with chronic kidney disease or those taking potassium-sparing agents), while amlodipine does not affect potassium levels. Lisinopril is absolutely contraindicated in pregnancy (FDA former category X for second and third trimesters), while amlodipine is classified as category C with limited human data.

Which Drug Works Better for Specific Patient Populations?

The 2017 ACC/AHA Hypertension Guideline recommends initiating therapy with an ACE inhibitor, ARB, CCB, or thiazide diuretic as first-line options, considering all four classes equivalent for the general hypertensive population. The selection between lisinopril and amlodipine depends on comorbidities and demographics.

Patients with diabetes or proteinuric kidney disease. ACE inhibitors, including lisinopril, have specific evidence for renal protection. The EUCLID trial and data from the RENAAL and IDNT studies (which tested ARBs, closely related to ACE inhibitors) support renin-angiotensin system blockade for slowing nephropathy progression. Amlodipine does not share this renal-protective signal. For a patient with type 2 diabetes and albuminuria, lisinopril is the preferred choice.

Black patients without CKD. ALLHAT data showed that lisinopril monotherapy was less effective at reducing blood pressure and stroke risk in Black participants compared to chlorthalidone. The International Society on Hypertension in Blacks (ISHIB) consensus statement recommends CCBs or thiazide diuretics as preferred initial monotherapy in this population. Amlodipine is often the better starting choice for a Black patient who does not have proteinuric kidney disease.

Patients with heart failure with reduced ejection fraction (HFrEF). ACE inhibitors are a pillar of HFrEF treatment with mortality data from SOLVD (N=2,569) and CONSENSUS. Amlodipine is considered safe in heart failure (unlike some other CCBs) based on the PRAISE trial, but it did not reduce mortality. Lisinopril is the clear pick here.

Post-myocardial infarction patients. ACE inhibitors reduce mortality after MI. The GISSI-3 trial and ISIS-4 trial both demonstrated benefit for lisinopril and captopril, respectively, in the post-MI setting. Amlodipine has no post-MI mortality benefit but is safe to use as add-on therapy for blood pressure control.

Elderly patients concerned about falls. Amlodipine does not cause the first-dose hypotension that can occur with ACE inhibitors. For a frail older adult, this can matter.

Prescribing Volume and Real-World Access Across the US

Lisinopril has been the most-prescribed antihypertensive in the United States for over a decade. According to ClinCalc data derived from the MEPS survey, lisinopril ranked as the 4th most commonly prescribed medication in the US in 2022, with an estimated 91 million prescriptions annually. Amlodipine ranked 8th with approximately 73 million annual prescriptions.

Both drugs are available at every retail pharmacy in the country. Neither requires specialty pharmacy distribution, cold chain storage, or REMS program enrollment. Prescriptions can be written by any licensed prescriber, from primary care physicians to nurse practitioners. Telehealth platforms, including HealthRX, can evaluate, prescribe, and ship both medications directly to patients.

Mail-order pharmacies offer additional savings. A 90-day supply of either drug typically costs $9 to $12 through Express Scripts, CVS Caremark, or OptumRx mail-order programs. Some Medicare Advantage plans offer $0 copays for both medications as part of preferred generic drug benefits.

Geographic access is essentially uniform. Unlike specialty medications or controlled substances, generic antihypertensives face no distribution bottlenecks, state-level restrictions, or supply chain vulnerabilities. During the 2023 drug shortage reports tracked by the FDA Drug Shortage Database, neither lisinopril nor amlodipine appeared on shortage lists.

When Combination Therapy Makes Both Drugs Relevant

Some patients will end up taking both lisinopril and amlodipine. The 2017 ACC/AHA guideline recommends initiating two first-line agents simultaneously when systolic blood pressure is 20 mmHg or more above goal, or when diastolic is 10 mmHg or more above goal. ACE inhibitor plus CCB is an evidence-backed combination.

The ACCOMPLISH trial (N=11,506) compared benazepril/amlodipine to benazepril/hydrochlorothiazide and found a 20% relative risk reduction in cardiovascular events favoring the ACE inhibitor plus CCB combination (HR 0.80 to 95% CI 0.72 to 0.90). While this trial used benazepril rather than lisinopril, the class effect is considered applicable. This combination also mitigates amlodipine-related ankle edema through the venodilatory effect of ACE inhibition.

The cost of taking both drugs together remains modest. A patient paying cash for lisinopril 20 mg plus amlodipine 5 mg would spend $6 to $20 per month total. With insurance, copays for two Tier 1 generics typically total $2 to $10 per month combined.

Fixed-dose combination pills containing an ACE inhibitor and amlodipine do exist (such as generic amlodipine-benazepril), though no fixed combination of lisinopril plus amlodipine is currently marketed. Patients who prefer a single daily pill may find the benazepril-amlodipine combination more convenient. Its generic cost runs $15 to $35 per month, still well within reach for most patients.

For a patient whose blood pressure remains above 130/80 on monotherapy, the clinical and economic argument for combining an ACE inhibitor with amlodipine is strong. The total monthly medication cost stays under $20 in nearly every scenario, and the ACCOMPLISH data suggest a cardiovascular benefit that exceeds what either agent provides alone.